目前前列腺癌特異性抗原檢測(cè)法（PSA）的益處是否大于傷害,，研究者們并不清楚，但是近日,，刊登在國(guó)際雜志Journal of Clinical Oncology上的一項(xiàng)研究報(bào)告指出,，長(zhǎng)壽的男性或許可以從PSA檢測(cè)法中獲得益處。
來(lái)自紐約Memorial Sloan-Kettering的研究者Ethan Basch博士進(jìn)行了PSA檢測(cè)法在男性前列腺癌中的實(shí)驗(yàn)研究,。研究人員發(fā)現(xiàn),，基于隨機(jī)比對(duì)臨床試驗(yàn)，PSA測(cè)試法可以降低前列腺癌死亡率,，但是研究者并不清楚其所帶來(lái)的益處是否超過(guò)篩查所引發(fā)的害處,。證據(jù)顯示，長(zhǎng)壽的男性可以從PSA測(cè)試法中獲得益處,，對(duì)于大多數(shù)男性來(lái)說(shuō),，前列腺活組織檢查相關(guān)的負(fù)面事件比較低，但是可以增加其感染的比率,，
研究者表示,，因?yàn)樽C據(jù)并不能清楚揭示PSA篩查的問(wèn)題，因此對(duì)于PSA篩查所引發(fā)的益處是否大于害處目前并不清楚,，不過(guò)未來(lái)研究者們希望通過(guò)深入研究確定其具體的利弊,。（生物谷Bioon.com）
編譯自：Benefits of prostate-specific antigen testing remain unclear
doi:10.1200/JCO.2012.43.3441
PMC:
PMID:
Screening for Prostate Cancer With Prostate-Specific Antigen Testing: American Society of Clinical Oncology Provisional Clinical Opinion
Ethan Basch, Thomas K. Oliver, Andrew Vickers, Ian Thompson, Philip Kantoff, Howard Parnes, D. Andrew Loblaw, Bruce Roth, James Williams and Robert K. Nam⇓
Purpose An American Society of Clinical Oncology (ASCO) provisional clinical opinion (PCO) offers timely clinical direction to the ASCO membership after publication or presentation of potentially practice-changing data from major studies. This PCO addresses the role of prostate-specific antigen (PSA) testing in the screening of men for prostate cancer. Clinical Context Prostate cancer is the second leading cause of cancer deaths among men in the United States. The rationale for screening men for prostate cancer is the potential to reduce the risk of death through early detection. Recent Data Evidence from a 2011 Agency for Healthcare Research and Quality systematic review primarily informs this PCO on the benefits and harms of PSA-based screening. An update search was conducted to March 16, 2012, for additional evidence related to the topic. Results In one randomized trial, PSA testing in men who would not otherwise have been screened resulted in reduced death rates from prostate cancer, but it is uncertain whether the size of the effect was worth the harms associated with screening and subsequent unnecessary treatment. Although there are limitations to the existing data, there is evidence to suggest that men with longer life expectancy may benefit from PSA testing. Adverse events associated with prostate biopsy are low for the majority of men; however, several population-based studies have shown increasing rates of infectious complications after prostate biopsy, which is a concern
